Cargando…
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
OBJECTIVE: This study was performed to compare health-related quality of life (HRQOL) of gemcitabine plus S-1 (GS), S-1 alone and gemcitabine alone as first-line chemotherapy for locally advanced or metastatic pancreatic cancer in the GEST (Gemcitabine and TS-1 Trial) study and to assess the impacts...
Autores principales: | Hagiwara, Yasuhiro, Ohashi, Yasuo, Okusaka, Takuji, Ueno, Hideki, Ioka, Tatsuya, Boku, Narikazu, Egawa, Shinichi, Hatori, Takashi, Furuse, Junji, Mizumoto, Kazuhiro, Ohkawa, Shinichi, Yamaguchi, Taketo, Yamao, Kenji, Funakoshi, Akihiro, Cheng, Ann-Lii, Kihara, Kiyohiro, Sato, Atsushi, Tanaka, Masao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
ESMO Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519786/ https://www.ncbi.nlm.nih.gov/pubmed/28761731 http://dx.doi.org/10.1136/esmoopen-2016-000151 |
Ejemplares similares
-
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2017) -
A multicenter phase II study of S-1 for gemcitabine-refractory biliary tract cancer
por: Suzuki, Eiichiro, et al.
Publicado: (2013) -
Efficacy and safety of axitinib in combination with gemcitabine in advanced pancreatic cancer: subgroup analyses by region, including Japan, from the global randomized Phase III trial
por: Ioka, Tatsuya, et al.
Publicado: (2015) -
Response to Y. Sasaki et al.: Is repeating FOLFIRINOX in the original dosage and treatment schedule tolerable in Japanese patients with pancreatic cancer?
por: Okusaka, Takuji, et al.
Publicado: (2015) -
Phase II study of FOLFIRINOX for chemotherapy-naïve Japanese patients with metastatic pancreatic cancer
por: Okusaka, Takuji, et al.
Publicado: (2014)